Net Income (Loss) Attributable to Parent in USD of Nurix Therapeutics, Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nurix Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2019 to Q3 2025.
  • Nurix Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Aug 2025 was -$86,421,000.000, a 76.5% decline year-over-year.
  • Nurix Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Aug 2025 was -$244,785,000.000, a 38.3% decline year-over-year.
  • Nurix Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$193,569,000.000, a 34.5% decline from 2023.
  • Nurix Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$143,948,000.000, a 20.2% increase from 2022.
  • Nurix Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$180,360,000.000, a 53.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Nurix Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$244,785,000 -$86,421,000 -$37,465,000 -76.5% 01 Jun 2025 31 Aug 2025 10-Q 09 Oct 2025
Q2 2025 -$207,320,000 -$43,464,000 +$1,082,000 +2.4% 01 Mar 2025 31 May 2025 10-Q 09 Oct 2025
Q1 2025 -$208,402,000 -$56,351,000 -$14,833,000 -35.7% 01 Dec 2024 28 Feb 2025 10-Q 09 Oct 2025
Q4 2024 -$193,569,000 -$58,549,000 -$16,593,000 -39.5% 01 Sep 2024 30 Nov 2024 10-K 28 Jan 2025
Q3 2024 -$176,976,000 -$48,956,000 -$11,974,000 -32.4% 01 Jun 2024 31 Aug 2024 10-Q 09 Oct 2025
Q2 2024 -$165,002,000 -$44,546,000 -$20,269,000 -83.5% 01 Mar 2024 31 May 2024 10-Q 09 Oct 2025
Q1 2024 -$144,733,000 -$41,518,000 -$785,000 -1.9% 01 Dec 2023 29 Feb 2024 10-Q 09 Oct 2025
Q4 2023 -$143,948,000 -$41,956,000 +$4,761,000 +10.2% 01 Sep 2023 30 Nov 2023 10-K 28 Jan 2025
Q3 2023 -$148,709,000 -$36,982,000 +$8,727,000 +19.1% 01 Jun 2023 31 Aug 2023 10-Q 11 Oct 2024
Q2 2023 -$157,436,000 -$24,277,000 +$21,124,000 +46.5% 01 Mar 2023 31 May 2023 10-Q 11 Oct 2024
Q1 2023 -$178,560,000 -$40,733,000 +$1,800,000 +4.2% 01 Dec 2022 28 Feb 2023 10-Q 11 Oct 2024
Q4 2022 -$180,360,000 -$46,717,000 -$9,015,000 -23.9% 01 Sep 2022 30 Nov 2022 10-K 28 Jan 2025
Q3 2022 -$171,345,000 -$45,709,000 -$16,874,000 -58.5% 01 Jun 2022 31 Aug 2022 10-Q 12 Oct 2023
Q2 2022 -$154,471,000 -$45,401,000 -$19,019,000 -72.1% 01 Mar 2022 31 May 2022 10-Q 12 Oct 2023
Q1 2022 -$135,452,000 -$42,533,000 -$18,258,000 -75.2% 01 Dec 2021 28 Feb 2022 10-Q 12 Oct 2023
Q4 2021 -$117,194,000 -$37,702,000 -$17,788,000 -89.3% 01 Sep 2021 30 Nov 2021 10-K 09 Feb 2023
Q3 2021 -$99,406,000 -$28,835,000 -$10,318,000 -55.7% 01 Jun 2021 31 Aug 2021 10-Q 06 Oct 2022
Q2 2021 -$89,088,000 -$26,382,000 -$33,962,000 -4.5% 01 Mar 2021 31 May 2021 10-Q 06 Oct 2022
Q1 2021 -$55,126,000 -$24,275,000 -$11,884,000 -95.9% 01 Dec 2020 28 Feb 2021 10-Q 06 Oct 2022
Q4 2020 -$43,242,000 -$19,914,000 -$6,395,000 -47.3% 01 Sep 2020 30 Nov 2020 10-K 16 Feb 2021
Q3 2020 -$36,847,000 -$18,517,000 -$16,090,000 -6.6% 01 Jun 2020 31 Aug 2020 10-Q 14 Oct 2021
Q2 2020 -$20,757,000 $7,580,000 +$10,648,000 01 Mar 2020 31 May 2020 10-Q 14 Oct 2021
Q1 2020 -$31,405,000 -$12,391,000 -$9,706,000 -3.6% 01 Dec 2019 29 Feb 2020 10-Q 14 Oct 2021
Q4 2019 -$21,699,000 -$13,519,000 01 Sep 2019 30 Nov 2019 10-K 16 Feb 2021
Q3 2019 -$2,427,000 01 Jun 2019 31 Aug 2019 10-K 16 Feb 2021
Q2 2019 -$3,068,000 01 Mar 2019 31 May 2019 10-K 16 Feb 2021
Q1 2019 -$2,685,000 01 Dec 2018 28 Feb 2019 10-K 16 Feb 2021

Nurix Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$193,569,000 -$49,621,000 -34.5% 01 Dec 2023 30 Nov 2024 10-K 28 Jan 2025
2023 -$143,948,000 +$36,412,000 +20.2% 01 Dec 2022 30 Nov 2023 10-K 28 Jan 2025
2022 -$180,360,000 -$63,166,000 -53.9% 01 Dec 2021 30 Nov 2022 10-K 28 Jan 2025
2021 -$117,194,000 -$73,952,000 -1.7% 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023
2020 -$43,242,000 -$21,543,000 -99.3% 01 Dec 2019 30 Nov 2020 10-K 28 Jan 2022
2019 -$21,699,000 01 Dec 2018 30 Nov 2019 10-K 28 Jan 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.